Skip to main content
Premium Trial:

Request an Annual Quote

CIRM Funds Dwindle

California's stem cell research agency may soon run out of funding, ScienceInsider reports.

The California Institute for Regenerative Medicine was established in 2004 following the passage of Proposition 71 and first began awarding grants in 2006. But as ScienceInsider reports, CIRM has announced that it has no more funding to award to new projects. At the end of June, the agency suspended application submissions until further notice, according to a note on its site.

"[T]here is no money available for new projects, whether it's discovery, translational, or clinical," CIRM's Kevin McCormack writes in a blog post.

ScienceInsider notes that the agency has sought bridge funding from private sources, though that has not been successful. There is also a push to again put stem cell research funding on the ballot in California with a $5.5 billion bond initiative, but ScienceInsider says its passage is not certain.

CIRM made California the "center of the stem cell universe. It would be tragic to unravel [that infrastructure] now," Jeanne Loring, who recently retired from the Scripps Research Institute and runs a biotech startup, tells it. "But the funding in 2004 was so dependent on the politics and interest at the time, and I don't know if those circumstances can be replicated."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.